All In MedTech

FDA Clearance Tracker · P100047-S115

HeartWare HVAD System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 26, 2018 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 26, 2018

Approved

Time to decision

269 days

Received Oct 30, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P100047-S115
Device name
HeartWare HVAD System
Applicant
Medtronic
Applicant location
Mounds View, MN
Received
Oct 30, 2017
Decided
Jul 26, 2018
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P100047

Device type

Device class
Class III
Specialty
Cardiology

Every decision under product code DSQ

FDA's approval statement

As written in FDA's record.

This device is indicated for hemodynamic support in patients with advanced, refractory leftventricular heart failure; either as a bridge to cardiac transplantation (BTT), myocardial recovery, or as destination therapy (DT) in patients for whom subsequent transplantation is not planned. We are pleased to inform you that the PMA supplement is approved.

Source documents

Other decisions for Medtronic

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.